Antares Pharma Inc Forecasted to Post Q2 2019 Earnings of $0.03 Per Share (ATRS)

Antares Pharma Inc (NASDAQ:ATRS) – Piper Jaffray Companies raised their Q2 2019 earnings per share (EPS) estimates for shares of Antares Pharma in a research report issued to clients and investors on Tuesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the specialty pharmaceutical company will earn $0.03 per share for the quarter, up from their prior forecast of $0.02. Piper Jaffray Companies has a “Buy” rating and a $4.00 price objective on the stock.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. The business had revenue of $17.87 million during the quarter, compared to the consensus estimate of $15.13 million. Antares Pharma had a negative return on equity of 56.80% and a negative net margin of 27.84%.

Other equities research analysts also recently issued reports about the company. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, July 17th. HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a report on Friday, August 17th. ValuEngine upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, August 8th. Finally, Jefferies Financial Group lifted their target price on Antares Pharma to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Antares Pharma currently has an average rating of “Buy” and a consensus target price of $5.44.

Shares of ATRS stock opened at $3.61 on Wednesday. The company has a market capitalization of $568.35 million, a price-to-earnings ratio of -32.82 and a beta of 0.55. The company has a quick ratio of 1.89, a current ratio of 2.33 and a debt-to-equity ratio of 1.01. Antares Pharma has a fifty-two week low of $1.60 and a fifty-two week high of $3.93.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MML Investors Services LLC increased its holdings in shares of Antares Pharma by 92.4% during the third quarter. MML Investors Services LLC now owns 40,600 shares of the specialty pharmaceutical company’s stock valued at $136,000 after acquiring an additional 19,500 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of Antares Pharma by 127.0% during the second quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after acquiring an additional 28,875 shares in the last quarter. United Services Automobile Association increased its holdings in shares of Antares Pharma by 1,453.0% during the second quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after acquiring an additional 379,166 shares in the last quarter. Perkins Capital Management Inc. increased its holdings in shares of Antares Pharma by 37.0% during the third quarter. Perkins Capital Management Inc. now owns 435,000 shares of the specialty pharmaceutical company’s stock valued at $1,462,000 after acquiring an additional 117,500 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Antares Pharma by 533.6% during the first quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 377,824 shares in the last quarter. Hedge funds and other institutional investors own 38.62% of the company’s stock.

In other Antares Pharma news, Director Jacques Gonella sold 49,507 shares of Antares Pharma stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $3.09, for a total value of $152,976.63. Following the completion of the sale, the director now directly owns 9,985,848 shares in the company, valued at $30,856,270.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert F. Apple sold 43,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total value of $161,250.00. Following the completion of the sale, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 492,507 shares of company stock valued at $1,830,227. 12.20% of the stock is currently owned by corporate insiders.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Article: What is a put option?

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply